

10/535307
Rec'd PCT/PTO 7 DEC 2005

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q87992

Andrew N. MARGIORIS, et al.

Appln. No.: 10/535,307

Group Art Unit: Not Yet Known

Confirmation No.: 3693

Examiner: Not Yet Known

Filed: May 18, 2005

For: USE OF THE CRH (CORTICOTROPIN RELEASING HORMONE) - UCN
(UROCORTIN) SYSTEM IN THE TREATMENT OF INFLAMMATORY DISEASES

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir: .

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after

INFORMATION DISCLOSURE STATEMENT


U.S. Appln. No.: 10/535,307

filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,



Brian W. Hannon
Registration No. 32,778

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: December 7, 2005

Substitute for Form 1449 A & B/PTO <u>INFORMATION DISCLOSURE</u> <u>STATEMENT BY APPLICANT</u> <i>(use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/535,307
				Confirmation Number	3693
				Filing Date	May 18, 2005
				First Named Inventor	Andrew N. MARGIORIS
				Art Unit	Not Yet Known
				Examiner Name	Not Yet Known
Sheet	1	of	2	Attorney Docket Number	Q87992

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		Corticotropin-Releasing Hormone augments Proinflammatory Cytokine Procution from Macrophages In Vitro and in Lipopolysaccharide-Induced Endotoxin shock in Mice; Agelaki, et al.; Infection and Immunity, November 2002, p. 6068-6074; Vol. 70, No. 11	
		Corticosteroid-independent inhibition of tumor necrosis factor production by the neuropeptide urocortin; Agnello, et al.; The American Physiological Society; E757-E760; XP-002247896	
		Corticosteroid-independent inhibition of tumor necrosis factor production by the neuropeptide urocortin; Agnello, et al.; AJP Endocrinology and Metabolism; http://ajpendo.physiology.org/cgi/content/full/275/5/E757	
		Receptor-mediated immunomodulation by corticotrophin-releasing factor; Audhya T, et al., Entrez PubMed; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi	
		mRNA expression profiles for corticotrophin-releasing factor 9CRF), urocortin, CRF receptors and CRF-binding protein in peripheral rat tissues; Baigent, et al.; Journal of Molecular Endocrinology (2000) 25, 43-52	
		Annals of the New York Academy of Sciences, Volume 917 2000; pp 290-296; The Peripheral CRH/Urocortin system; Bamberger, et al.; http://lib3.tufts.edu:2301/gw1/ovidweb.cgi	
		CRH-like peptides protect cardiac myocytes from lethal ischaemic injury; Brar BK, et al.; Pub Med; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?	
		Local Secretion of Corticotropin-releasing Hormone in the Joints of Lewis Rats with Inflammatory Arthritis; Crofford, et al.; The Journal of Clinical Investigation, Inc., Volume 90, December 1992, 2555-2564	
		Corticotropin-Releasing hormone in Synovial Fluids and Tissues of patients with Rheumatoid Arthritis and osteoarthritis; Crofford, et al.; The Journal of immunology; Vol. 151, 1587-1596, No. 3, august 1, 1993	
		The CRF peptide family and their receptors: yet more partners discovered; Dautzenberg, et al.; Trends in Pharmacological Sciences; Vol. 23, No. 2, February 2002	
		Corticotropin-releasing Hormone Induces Fas Ligand Production and Apoptosis in PC12 Cells via Activation of p38 Mitogen-activated Protein Kinase; Dermitzaki, et al.; The Journal of Biological Chemistry; vol. 277, No. 14; April 5, 2002; pp. 12280-12287	
		Stress Hormones, Th1/Th2 patterns, Pro/Anti-inflammatory Cytokines and Susceptibility to Disease; Elenkov, et al. TEM, vol. 10, No. 9, 1999; pp. 359-379	
		Annals of the New York Academy of Sciences; Stress, Corticotropin-Releasing Hormone, Glucocorticoids, and the Immune/Inflammatory Response: Acute and Chronic Effects; Elenkov, et al.; Vol. 876; pp. 1-13; http://lib3.tufts.edu:2301/gw1/ovidweb.cgi	
		Urocortin 1 and urocortin 2 induce macrophage apoptosis via CRFR ₂ ; Tsatsanis, et al.; 2005 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies;	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.

Substitute for Form 1449 A & B/PTO <u>INFORMATION DISCLOSURE</u> <u>STATEMENT BY APPLICANT</u> <i>(use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/535,307
				Confirmation Number	3693
				Filing Date	May 18, 2005
				First Named Inventor	Andrew N. MARGIORIS
				Art Unit	Not Yet Known
				Examiner Name	Not Yet Known
Sheet 2 of 2				Attorney Docket Number	Q87992

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		Anal of the New York Academy of Sciences; Stress, Corticotropin-Releasing Hormone, Glucocorticoids, and the Immune/Inflammatory Response: Acute and Chronic Effects; Elenkov, et al.; Volume 8760.1999.1-13	
		Autocrine or paracrine inflammatory actions of corticotrophin-releasing hormone in vivo.; Karalis, et al.; National Library of Medicine; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?	
		Corticotropin releasing hormone in colonic mucosa in patients with ulcerative colitis; Kawahito, et al.; National Library of Medicine; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=	
		Urocortin Expression in Synovium of Patients with Rheumatoid Arthritis and osteoarthritis: Relation to Inflammatory Activity; Kohno, et al.; The Journal of Clinical Endocrinology & Metabolism 86(9) 4344-4352	
		Differential Actions of peripheral Corticotropin-Releasing Factor (CRF), Urocortin II, and Urocortin III on Gastric Emptying and Colonic Transit in Mice: role of CRF Receptor Subtypes 1 and 2; Martinez, et al.; The Journal of Pharmacology and Experimental Therapeutics; Vol. 301, No. 2; pp. 611-617	
		Human urocortin II, a new CRF-related peptide, displays selective CRF 2-mediated action on gastric transit in rats; Million, et al.; American Journal of Physiology -- Gastrointestinal and Liver Physiology; September 21, 2001; pp. G34-G40.	
		Urocortin and corticotrophin-releasing factor receptor expression in the human colonic mucosa; Muramatsu, et al.; Peptides 21 92000) 1799-1809	
		Urocortin, a member of the corticotrophin-releasing factor family, in normal and diseased heart; Nishikimi, et al.; American Journal of Physiology Heart Circ Physiol 279: H:3031-H3039, 2000	
		Urocortin, But Not Urocortin II, Protects Cultured Hippocampal Neurons From oxidative and Excitotoxic Cell Death via Corticotropin-Releasing Hormone Receptor Type I; Pedersen, et al.; The Journal of Neuroscience, January 15, 2002, 22(2):404-412	
		Corticotropin Releasing Factor Receptors and Their Ligand Family; Perrin, et al.; Academy of Science, Volume 8850.1999.312-328; http://lib3.tufts.edu:2301/gw1/ovidweb.cgi	
		Stress and Autoimmunity; The Neuropeptides Corticotropin-Releasing Factor and Urocortin Suppress Encephalomyelitis via Effects on Both the Hypothalamic-Pituitary-Adrenal Axis and the Immune System; Poliak, et al.; the American Association of immunologists; 1997; 158: 5751-5756	
		Corticotropin-Releasing hormone induces Skin Mast Cell Degranulation and Increased Vascular Permeability, A Possible Explanation for Its Proinflammatory Effects; The Endocrine Society; Vol. 139. No. 1;	
		Urocortin, a corticotrophin-releasing factor-related mammalian peptide, inhibits edema due to thermal injury in rats; Turnbull, et al.; Pub Med; National Library of Medicine; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?	
		Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotrophin-releasing factors; Vaughan, et al.; Letters to Nature; Vol. 378, November 16, 1995	
		Corticotropin-releasing factor receptors in mouse spleen: identification of receptor-bearing cells as resident macrophages; Webster, et al.; Pub Med; National Library of Medicine; July 1990; 127(1):440-52; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?	
		Corticotropin-Releasing Hormone and Inflammation; Annals of the New York Academy of Sciences; Volume 840; 1998; pp 21-32	
		Urocortin in Human Gastric Mucosa: Relationship to Inflammatory Activity; Chatzaki, et al.; The Journal of Clinical Endocrinology & Metabolism; 88(1):478-483	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.